NervGen released expanded CONNECT phase Ib/IIa data showing that NVG‑291, a 35‑amino‑acid peptide, produced durable functional improvements in people with chronic spinal cord injury that persisted past the 12‑week treatment window to week 16 and beyond. The company reported participant‑reported gains in bladder control and reductions in spasticity, objective neurophysiology changes consistent with repair mechanisms, and positive blinded exit interviews up to one year. NervGen completed an FDA Type C meeting where regulators confirmed multiple potential approval pathways, setting the stage for further discussions on pivotal study design.